Compare Recursion Pharmaceuticals Inc (RXRX) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sprott Uranium Miners ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Sprott Uranium Miners ETF trades at $50.11. Which is the better fit depends on your goals.
| RXRX | URNM | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $83.99 |
52-Week Low | $2.84 | $44.14 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
URNM trades at $48.25, up 0.06% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF focuses on uranium miners, benefiting from rising nuclear energy demand driven by AI power needs. Recent news highlights strong performance, with URNM up 26% year-to-date as of April 2026, though some articles question miner valuations versus uranium prices.
The outlook for URNM is supported by long-term nuclear energy growth, but risks include volatility in uranium prices and concentrated miner exposure. Analyst sentiment is mixed, with some seeing upside from AI-driven power demand, while others caution on supply chain gaps and equity optimism diverging from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
